Sera Prognostics Inc (Sera Prognostics) is a biotechnology firm, that specializes in providing diagnostic tests for predicting the risk of pregnancy complications such as premature birth and preeclampsia. It offers PreTRM, a proteomic predictor of premature birth risk for clinicians, mothers and doctors to deliver personalized care plans and treatments for improving the newborn and maternal health. The company’s biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression. Sera Prognostics is headquartered in Salt Lake, Utah, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Sera Prognostics Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Sera Prognostics Inc Company Overview
Sera Prognostics Inc Company Snapshot
Sera Prognostics Inc Pipeline Products and Ongoing Clinical Trials Overview
Sera Prognostics Inc – Pipeline Analysis Overview
Sera Prognostics Inc - Key Facts
Sera Prognostics Inc - Major Products and Services
Sera Prognostics Inc Pipeline Products by Development Stage
Sera Prognostics Inc Pipeline Products Overview
Biomarker Test - Fetal Growth Restriction
Biomarker Test - Fetal Growth Restriction Product Overview
Biomarker Test - Gestational Diabetes Mellitus
Biomarker Test - Gestational Diabetes Mellitus Product Overview
Biomarker Test - Molecular Time-to-Birth
Biomarker Test - Molecular Time-to-Birth Product Overview
Biomarker Test - Postpartum Depression
Biomarker Test - Postpartum Depression Product Overview
Biomarker Test - Stillbirth
Biomarker Test - Stillbirth Product Overview
Diagnostic Test - Preeclampsia
Diagnostic Test - Preeclampsia Product Overview
Predictive Analytics Test
Predictive Analytics Test Product Overview
Pregnancy Risk Prediction Panel
Pregnancy Risk Prediction Panel Product Overview
Sera Prognostics Inc - Key Competitors
Sera Prognostics Inc - Key Employees
Sera Prognostics Inc - Locations And Subsidiaries
Head Office
Recent Developments
Sera Prognostics Inc, Recent Developments
Nov 08, 2023: Sera Prognostics Reports First Quarter 2023 Financial Results
Oct 25, 2023: Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023
Aug 09, 2023: Sera Prognostics Reports Second Quarter 2023 Financial Results
May 22, 2023: Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue
May 15, 2023: Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
Feb 16, 2023: Sera Prognostics reports data from PreTRM test trial
Nov 29, 2022: Fors Marsh to include the Pretrm Test in its employee maternity benefits package in collaboration with Sera Prognostics
Nov 15, 2022: Sera Prognostics announces publication of data predicting clinical utility and cost effectiveness of the PreTRM test-and-treat strategy across diverse populations
Oct 04, 2022: Sonrava Health to include the PreTRM test in its employee maternity benefits package in collaboration with Cerebrae and Sera Prognostics
Sep 22, 2022: Banner Health, Sera Prognostics Team Up to Provide PreTRM Test to Covered Pregnant Members
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Sera Prognostics Inc Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Sera Prognostics Inc Pipeline Products by Equipment Type
Table 3: Sera Prognostics Inc Pipeline Products by Indication
Table 4: Sera Prognostics Inc, Key Facts
Table 5: Sera Prognostics Inc, Major Products and Services
Table 6: Sera Prognostics Inc Number of Pipeline Products by Development Stage
Table 7: Sera Prognostics Inc Pipeline Products Summary by Development Stage
Table 8: Biomarker Test - Fetal Growth Restriction - Product Status